[Remote] Senior Director, Government Accounts & Policy at Axsome Therapeutics Inc

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

12+ years of experience in Market Access environment
BS/BA required, MBA preferred
Previous Field Sales, Sales Management and Government Affairs
Established relationships with key government payer agencies
Highly developed business skills, including organizational, strategic planning, excellent written and oral communication, superb persuasive abilities
Highly self-motivated
Strong selling skills
Ability to navigate change by quickly focusing on critical issues and prioritizing
Leads with strategic agility, developing innovative strategies and pragmatic solutions
Develops organizational capability by fostering growth in the organization

Responsibilities

Primary contact with all government payers
Analyzes government payer market dynamics and sets goals to ensure profitable access
Develops and maintains a well-thought-out data-driven strategic plan
Collaborates with Legal to develop and execute legislative and government affairs plans affecting access
Maintains excellent relationships with key government payers and agencies
Communicates information to the field sales force to enhance government payer pull through opportunities
Leads government payer coverage of Vera's entire product portfolio
Develops action plans related to legislation and regulations affecting access to Vera's products
Protects and grows Medicaid access for the entire product portfolio
Works with cross-functional teams, including Market Access, Commercial, Legal, Medical Affairs, Government Affairs, and Sales, to achieve goals

Skills

Government Affairs

Policy Development

Cross-functional Collaboration

Strategic Planning

Market Access

Regulatory Affairs

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free